Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
{{output}}
Aim: We evaluated the efficacy of a novel switch protocol for EGFR-TKIs for EGFR mutation-positive NSCLC. Materials & methods: Clinical records... ...
